Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have become standard of care for many peritoneal malignancies in selected patients. Nevertheless, this aggressive treatment strategy is associated with significant major morbidity. The aim of the present study is to analyze the re-operation rate and clinical outcome following CRS and HIPEC. In the present study, prospectively documented data of 474 consecutive...